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Objectives: Dosing frequency appears to be an important determinant of adherence to oral bisphosphonate treatment in
postmenopausal osteoporosis (PMO). The potent, nitrogen-containing bisphosphonate, ibandronate (Bonviva), is effective and
well tolerated when administered orally, using either a daily or intermittent dosing schedule (dosing interval >2 months; 3-year
vertebral fracture risk reduction: 62% and 50%, respectively). In the MOBILE study, once-monthly oral ibandronate dosing was
at least as effective as daily dosing with respect to improvements in lumbar spine BMD at 12 months (Table). A retrospective
non-inferiority/superiority analysis compared the changes in proximal femur BMD observed with the daily and once-monthly
regimens after 12 months.
Methods: MOBILE is a 2-year, randomised, double-blind, phase III, non-inferiority study, which involved 1,609 women (aged
55–80 years; ≥ 5 years since menopause) with PMO (lumbar spine BMD T-score <–2.5 and ≥ –5). Oral ibandronate was
administered either daily (2.5mg) or monthly as 50/50mg (single doses, consecutive days), 100mg (single day) or 150mg (single
day). All participants also received calcium (500mg) and vitamin D (400 IU) supplements. Changes (%) in total hip, femoral neck
and hip trochanter BMD were evaluated after 12 months of treatment. Margins of non-inferiority were determined based on the
differences between daily ibandronate and placebo in the BONE study. Confidence intervals (95% CI) for the difference in mean
values between each monthly group and the daily comparator were used to determine non-inferiority and superiority.
Results: Treatment with either daily or monthly ibandronate resulted in marked increases in proximal femur BMD after 12
months (Table). Increases in total hip and hip trochanter BMD achieved with the 50/50mg, 100mg and 150mg once-monthly
regimens were statistically non-inferior to those achieved with daily dosing (margin: –0.60% and –0.72%, respectively; Table). In
addition, both 100mg and 150mg monthly regimens were statistically superior to daily dosing (Table). With regard to femoral
neck BMD, non-inferior increases versus daily dosing were observed with both the 100mg and 150mg monthly regimens
(margin: –0.44%; Table).
Change in BMD from baseline (%; 95% CI of difference vs
daily)
2.5mg daily 50/50mg monthly 100mg monthly 150mg monthly
(n=318) (n=326) (n=311) (n=320)
Lumbar spine 3.9 4.3 (–0.09,1.12)* 4.1 (–0.42, 0.81)* 4.9 (0.38, 1.60)*†
Total hip 2.0 2.2 (–0.16, 0.70)* 2.7 (0.31, 1.18)*† 3.1 (0.64, 1.50)*†
Femoral neck 1.7 1.8 (–0.45, 0.63) 1.9 (–0.34, 0.76)* 2.2 (–0.04, 1.05)*
Trochanter 3.2 3.5 (–0.29, 0.97)* 3.9 (0.06, 1.33)*† 4.6 (0.82, 2.08)*†
*non-inferior and/or †superior vs daily
*non-inferior and/or †superior vs daily
Conclusion: This analysis suggests that once-monthly oral ibandronate dosing is at least as efficacious as daily dosing in
improving hip BMD in women with PMO.
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